--- 
layout: page 
image:
  feature: DaubEnginePatent.jpg
--- 
   <head>
      <title>2429-</title>
      <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
</head>
      <li><a href="index.html">Manual of Patent Examining Procedure</a></li>
      <li><a href="mpep-2400.html"><span>Chapter 2400</span></a></li>
      <li><span>Section 2429</span></li>  </ul>  </div>
      <div id="yui-main">
         <div class="yui-b">
            <div class="yui-g">  <div xmlns:bf="http://www.uspto.gov/bf" id="article">
               <div>
                  <div xmlns="" class="Section" id="d0e247577">
                     <h1 class="page-title">2429
                        &nbsp;&nbsp;
                        Helpful Hints for Compliance [R-08.2012]
                     </h1>
                     <p id="d0e247581">The Office has now had a good deal of
                        experience in the implementation of the sequence rules. The following list sets forth
                        helpful hints, for both examiners and applicants, for compliance. For the most part, the
                        list is a compilation of frequently asked questions. 
                     </p>
                     <p id="d0e247584">—Compliance is not a filing date issue. </p>
                     <p id="d0e247587">—Compliance is not a <b><a href="mpep-9015-appx-l.html#d0e302824">35 U.S.C.
                              112</a></b> issue.
                     </p>
                     <p id="d0e247593">—Compliance is not a <b><a href="mpep-9015-appx-l.html#d0e302921">35 U.S.C.
                              119</a></b>/120 issue.
                     </p>
                     <p id="d0e247599">—Compliance is not <i>per se </i>a new matter issue. The standard for resolution of
                        inconsistencies between the official “Sequence Listing” (submitted on paper or compact disc
                        pursuant to <b><a href="mpep-9020-appx-r.html#d0e333653">37 CFR 1.821(c)</a></b>) and the computer
                        readable form thereof and/or errors in the official copy of sequence information is based
                        on the new matter standard. If there are inconsistencies in compact discs submitted in
                        accordance with <b><a href="mpep-9020-appx-r.html#d0e318327">37 CFR 1.52(e)</a></b> between “Copy 1” and
                        “Copy 2”, the compact disc labeled “Copy 1” will be used for further
                        processing.
                     </p>
                     <p id="d0e247611">—Compliance can be achieved via
                        amendment. 
                     </p>
                     <p id="d0e247614">—The paper or compact disc copy of the
                        Sequence Listing is an integral part of the application. If submitted on paper, the
                        Sequence Listing must begin on a new page, should appear at the end of the application, and
                        preferably should be numbered independently of the numbering of the remainder of the
                        application. The new page that begins the “Sequence Listing” should be entitled “Sequence
                        Listing.” If not submitted as such at filing, the Sequence Listing must be inserted into
                        the application via amendment, e.g., by preliminary amendment. If submitted on compact
                        disc, the specification must contain an incorporation by reference of the material on the
                        compact disc in a separate paragraph identifying each compact disc.
                     </p>
                     <p id="d0e247617">—Substitute pages or replacement
                        compact discs must be used for changes to the Sequence Listing for each respective
                        format.
                     </p>
                     <p id="d0e247620">—Angle brackets and numeric identifiers
                        listed in <b><a href="mpep-9020-appx-r.html#d0e333837">37 CFR 1.823</a></b> are very important for our
                        database. Extra punctuation should not be used in Sequence Listings.
                     </p>
                     <p id="d0e247626">—The computer readable form cannot
                        contain page numbers. Page numbers should only be placed on the paper copy of the Sequence
                        Listing. Page numbers should not be placed on the compact disc copy of the Sequence
                        Listing. 
                     </p>
                     <p id="d0e247629">—The PatentIn computer program is not
                        the only means by which to comply with the rules. Any word processing program can be used
                        to generate a Sequence Listing if it has the capability to convert a file into ASCII
                        text.
                     </p>
                     <p id="d0e247632">—If a word processing program is used
                        to generate a “Sequence Listing,” hard page break controls should not be used and margins
                        should be adjusted to the smallest setting.
                     </p>
                     <p id="d0e247635">—Word processing files should not be
                        submitted to the Office; the Sequence Listing generated by a word processing file should be
                        saved as an ASCII text file for submission. Most word processing programs provide this
                        feature.
                     </p>
                     <p id="d0e247638">—Statements in accordance with
                        <b><a href="mpep-9020-appx-r.html#d0e333653">37
                              CFR 1.821(f)</a></b>, (g), (h) and <b><a href="mpep-9020-appx-r.html#d0e334511">37 CFR 1.825</a></b> and
                        proper labeling in accordance with <b><a href="mpep-9020-appx-r.html#d0e334418">37 CFR 1.824(a)</a></b>(6) should be noted.
                        Sample statements to support filings and submissions in accordance with <b><a href="mpep-9020-appx-r.html#d0e333653">37 CFR
                              1.821</a></b> through 1.825 are provided in <b><a href="s2428.html#d0e247518">MPEP §
                              2428</a></b> Sample Statements.
                     </p>
                     <p id="d0e247656">—Use Box SEQUENCE.</p>
                     <p id="d0e247659">—Three and a half inch disks are less
                        fragile than five and a quarter inch disks.
                     </p>
                     <p id="d0e247662">—On nucleotide sequences, since only
                        single strands may be depicted in the “Sequence Listing,” show strands in 5′ to 3′
                        direction.
                     </p>
                     <p id="d0e247665">—The single stranded nucleotide
                        depicted in the “Sequence Listing” may represent a strand of a nucleotide sequence that may
                        be single or double stranded which may be, further, linear or circular. An amino acid
                        sequence or peptide may be linear or circular. In some instances, a sequence may be both
                        single stranded and double stranded and/or both linear and circular. The response “not
                        relevant” is also an acceptable response for both “Strandedness” and “Topology.” 
                     </p>
                     <p id="d0e247668">—Numeric identifiers “&lt;140&gt;,
                        Current Application Number,” “&lt;141&gt;, Current Filing Date,” “&lt;150&gt;, Prior
                        Application Number,” and “&lt;151&gt;, Prior Application Filing Date,” should appear in the
                        “Sequence Listing” in all cases. If the information about the current application is not
                        known or is unavailable at the time of completing the Sequence Listing, then the lines
                        following numeric identifiers &lt;140&gt; and &lt;141&gt; should be left blank. This would
                        normally be the case when the “Sequence Listing” is included in a newly filed application.
                        Similarly, if information regarding prior applications is inapplicable, or not known at the
                        time of completing the “Sequence Listing” but will be later filed, then the numeric
                        identifiers &lt;150&gt; and &lt;151&gt; should appear with the line following the numeric
                        identifiers left blank. 
                     </p>
                     <p id="d0e247671">—If you receive a Notice to Comply that
                        should not have been sent to you, send a letter in the form of a request for
                        reconsideration of the notice to the organization sending the notice.
                     </p>
                     <p id="d0e247674">—There are a limited number of
                        mandatory items of information. They are identified in <b><a href="s2424.html#d0e246289">MPEP
                              §&nbsp;2424.02</a></b> Sequence Listing Numeric Identifiers.
                     </p>
                     <p id="d0e247680">—Figures can be used to convey
                        information not readily conveyed by the Sequence Listing. The exclusive conformance
                        requirement of <b><a href="mpep-9020-appx-r.html#d0e333653">37 CFR 1.821(b)</a></b> will be relaxed for
                        drawing figures. However, the sequence information so conveyed must still be included in a
                        “Sequence Listing” and the sequence identifier (“SEQ ID NO:X”) must be used, either in the
                        drawing or in the “Brief Description of the Drawings.” 
                     </p>
                     <p id="d0e247686">—Extra copies of computer readable
                        forms should not be sent to examiners.
                     </p>
                     <p id="d0e247689"> —Inosine may be represented by the use
                        of “I” in the features section, otherwise use “n.”
                     </p>
                     <p id="d0e247692"> —Stop codons, represented by an
                        asterisk, are not permitted in amino acid sequences.
                     </p>
                     <p id="d0e247695"> —Punctuation should not be used in a
                        sequence to indicate unknown nucleotide bases or amino acid residues nor should punctuation
                        be used to delimit active or functional regions of a sequence. These regions should be
                        noted as Features of the sequence per <b><a href="mpep-9020-appx-r.html#d0e333837">37&nbsp;CFR 1.823(b)</a></b> (see numeric
                        identifiers &lt;220&gt; - &lt;223&gt;.
                     </p>
                     <p id="d0e247701">—The presence of an unnatural amino
                        acid in a sequence does not have the same effect as the presence of a D-amino acid. The
                        sequence may still be subject to the rules even though one or more of the amino acids is
                        not naturally occurring.
                     </p>
                     <p id="d0e247704">—Cyclic and branched peptides are
                        causing some confusion in the application of the rules. Specific questions should be
                        directed to Group 1650 personnel. 
                     </p>
                     <p id="d0e247707">—A cyclic peptide with a tail is
                        regarded as a branched sequence, and thereby exempt from the rules, if all bonds adjacent
                        to the amino acid from which the tail emanates are normal peptide bonds.
                     </p>
                     <p id="d0e247710">—Sequences that have variable-length
                        regions depicted as, for example, Ala Ala Leu Leu (Xaa Xaa)<sub>n</sub> Ile Pro where n=0-234 or agccttgggaca(nnnnn)<sub>m</sub>gtcatt where m=0-354 or Ser Met Ala Xaa Ser where Xaa could be 1, 2, 3, 4
                        <span class="Underline">and/or</span> 5 amino acids must still comply with the
                        Sequence Rules. The method to use is to repeat the variable-length region as many times as
                        the maximum length and specify in the Features section that the amino acid (or nucleotide)
                        at a specified position is either absent or present. The variables Xaa and n may stand for
                        only one residue, hence the need to repeat the variable. The correct way to submit the
                        third example is Ser Met Ala Xaa Xaa Xaa Xaa Xaa Ser combined with an explanation in the
                        Features section of the listing that any one or all of amino acids 4-8 can either be
                        present or absent.
                     </p>
                     <p id="d0e247722">—Single letter amino acid abbreviations
                        are not acceptable within the Sequence Listing but may appear elsewhere in the
                        application.
                     </p>
                     <p id="d0e247725">—Zero (0) is not used when the
                        numbering of amino acids uses negative numbers to distinguish the mature
                        protein.
                     </p>
                     <p id="d0e247728">—Subscripts or superscripts are not
                        permitted in a Sequence Listing. 
                     </p>
                     <p id="d0e247731">—If a “Sequence Listing” is amended, an
                        entirely new computer readable form is required regardless of the triviality of the
                        amendment. Amendments to the paper copy of the “Sequence Listing” must be made by
                        replacement section in compliance with <b><a href="mpep-9020-appx-r.html#d0e323020">37 CFR 1.121</a></b>. Amendments to the compact
                        disc copy of the “Sequence Listing” must be made by replacement discs. 
                     </p>
                     <p id="d0e247737">—Note field length limitations. For
                        specific instances, they may be waived, but compliance is encouraged.
                     </p>
                     <p id="d0e247744">—The exclusive conformance requirement
                        of <b><a href="mpep-9020-appx-r.html#d0e333653">37&nbsp;CFR 1.821(b)</a></b> requires that any amendment of the sequence
                        information in a “Sequence Listing” be accompanied by an amendment to the corresponding
                        information, if any, embedded in the text of the specification or presented in a drawing
                        figure. 
                     </p>
                     <p id="d0e247750">—Any inquiries regarding a specific
                        computer readable form that has been processed by the Office should be directed to the
                        Systems Branch of the Chemical/Biotechnology Division of the Scientific and Technical
                        Information Center.
                     </p>
                     <p align="right"><a href="#top">[top]</a></p>
                  </div>
               </div>
               <div>
                  <h1 class="page-title">&nbsp;</h1>
               </div>  </div>
            </div>
         </div>
      </div>
      <div class="yui-b">
         <div id="aside">  <div id="rdms-sub-nav-container" xmlns:bf="http://www.uspto.gov/bf">
            <ul id="sub-nav">
               <li xmlns=""><a href="s2401.html">2401-Introduction</a></li>
               <li xmlns=""><a href="s2402.html">2402-The Deposit Rules</a></li>
               <li xmlns=""><a href="s2403.html">2403-Deposit of Biological Material</a><ul>
                     <li><a href="s2403.html#d0e240728">2403.01-Material Capable of Self- Replication</a></li>
                     <li><a href="s2403.html#d0e240735">2403.02-Plant Material</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2404.html">2404-Need or Opportunity to Make a Deposit</a><ul>
                     <li><a href="s2404.html#d0e240816">2404.01-Biological Material That Is Known and Readily Available to the Public</a></li>
                     <li><a href="s2404.html#d0e240930">2404.02-Biological Material That Can Be Made or Isolated Without Undue Experimentation</a></li>
                     <li><a href="s2404.html#d0e240946">2404.03-Reference to a Deposit in the Specification</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2405.html">2405-Acceptable Depository</a></li>
               <li xmlns=""><a href="s2406.html">2406-Time of Making an Original Deposit</a><ul>
                     <li><a href="s2406.html#d0e241742">2406.01-Description in Application Specification</a></li>
                     <li><a href="s2406.html#d0e241769">2406.02-Deposit After Filing Date - Corroboration</a></li>
                     <li><a href="s2406.html#d0e241779">2406.03-Possible Loss of U.S. Filing Date in Other Countries</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2407.html">2407-Replacement or Supplement of Deposit</a><ul>
                     <li><a href="s2407.html#d0e241898">2407.01-In a Pending Application</a></li>
                     <li><a href="s2407.html#d0e241922">2407.02-After a Patent Has Issued</a></li>
                     <li><a href="s2407.html#d0e241949">2407.03-Failure to Replace</a></li>
                     <li><a href="s2407.html#d0e241964">2407.04-Treatment of Replacement</a></li>
                     <li><a href="s2407.html#d0e241982">2407.05-Exemption From Replacement</a></li>
                     <li><a href="s2407.html#d0e241992">2407.06-Replacement May Not Be Recognized</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2408.html">2408-Term of Deposit</a></li>
               <li xmlns=""><a href="s2409.html">2409-Viability of Deposit</a></li>
               <li xmlns=""><a href="s2410.html">2410-Furnishing of Samples</a><ul>
                     <li><a href="s2410.html#d0e242157">2410.01-Conditions of Deposit</a></li>
                     <li><a href="s2410.html#d0e242206">2410.02-Certification of Statement of Availability of Deposit</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2411.html">2411-Examination Procedures</a><ul>
                     <li><a href="s2411.html#d0e242312">2411.01-Rejections Based on Deposit Issue</a></li>
                     <li><a href="s2411.html#d0e242401">2411.02-Replies to Rejections Based on Deposit Issue</a></li>
                     <li><a href="s2411.html#d0e242424">2411.03-Application in Condition for Allowance Except for Deposit</a></li>
                     <li><a href="s2411.html#d0e242459">2411.04-After a Patent Has Been Granted</a></li>
                     <li><a href="s2411.html#d0e242505">2411.05-Content of Application with Respect to Deposited Material</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2412-2419.html">2412-2419-[Reserved]</a></li>
               <li xmlns=""><a href="s2420.html">2420-The Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures - the Sequence
                     Rules</a></li>
               <li xmlns=""><a href="s2421.html">2421-Overview of the Sequence Rules</a><ul>
                     <li><a href="s2421.html#d0e242552">2421.01-Applications Affected</a></li>
                     <li><a href="s2421.html#d0e242568">2421.02-Summary of the Requirements of the Sequence Rules</a></li>
                     <li><a href="s2421.html#d0e242594">2421.03-Notification of a Failure to Comply</a></li>
                     <li><a href="s2421.html#d0e242622">2421.04-Future Changes to the Sequence Rules</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2422.html">2422-Nucleotide and/or Amino Acid Sequence Disclosures in Patent Applications</a><ul>
                     <li><a href="s2422.html#d0e245121">2422.01-Definitions of Nucleotide and/or Amino Acids for Purpose of Sequence Rules</a></li>
                     <li><a href="s2422.html#d0e245175">2422.02-The Requirement for Exclusive Conformance; Sequences Presented in Drawing Figures</a></li>
                     <li><a href="s2422.html#d0e245191">2422.03-The Requirements for a Sequence Listing and Sequence Identifiers; Sequences Embedded in Application Text; Variants of a Presented
                           Sequence</a></li>
                     <li><a href="s2422.html#d0e245299">2422.04-The Requirement for a Computer Readable Copy of the Official Copy of the Sequence Listing</a></li>
                     <li><a href="s2422.html#d0e245330">2422.05-Reference to Previously Filed Identical Computer Readable Form; Continuing or Derivative Applications; Request for Transfer
                           of Computer Readable Form</a></li>
                     <li><a href="s2422.html#d0e245358">2422.06-Requirement for Statement Regarding Content of Official and Computer Readable Copies of Sequence Listing</a></li>
                     <li><a href="s2422.html#d0e245376">2422.07-Requirements for Compliance, Statements Regarding New Matter, and Sanctions for Failure to Comply</a></li>
                     <li><a href="s2422.html#d0e245454">2422.08-Presumptions Regarding Compliance</a></li>
                     <li><a href="s2422.html#d0e245470">2422.09-Box Sequence; Hand Delivery of Sequence Listings and Computer Readable Forms</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2423.html">2423-Symbols and Format To Be Used for Nucleotide and/or Amino Acid Sequence Data</a><ul>
                     <li><a href="s2423.html#d0e245579">2423.01-Format and Symbols To Be Used in Sequence Listings</a></li>
                     <li><a href="s2423.html#d0e245618">2423.02-Depiction of Coding Regions</a></li>
                     <li><a href="s2423.html#d0e245637">2423.03-Presentation and Enumeration of Sequences</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2424.html">2424-Requirements for Nucleotide and/or Amino Acid Sequences as Part of the Application Papers</a><ul>
                     <li><a href="s2424.html#d0e246252">2424.01-Informational Requirements for the Sequence Listing</a></li>
                     <li><a href="s2424.html#d0e246289">2424.02-Sequence Listing Numeric Identifiers</a></li>
                     <li><a href="s2424.html#d0e246838">2424.03-Additional Miscellaneous Requirements</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2425.html">2425-Form and Format for Nucleotide and/or Amino Acid Sequence Submissions in Computer Readable Form</a></li>
               <li xmlns=""><a href="s2426.html">2426-Amendments to or Replacement of Sequence Listing and Computer Readable Copy Thereof</a></li>
               <li xmlns=""><a href="s2427.html">2427-Form Paragraphs and Notice to Comply</a><ul>
                     <li><a href="s2427.html#d0e247062">2427.01-Form Paragraphs</a></li>
                     <li><a href="s2427.html#d0e247506">2427.02-Notice To Comply</a></li>
                  </ul>
               </li>
               <li xmlns=""><a href="s2428.html">2428-Sample Statements</a></li>
               <li xmlns=""><a href="s2429.html">2429-Helpful Hints for Compliance</a></li>
               <li xmlns=""><a href="s2430.html">2430-PatentIn Information; Utilities Programs; Training</a></li>
               <li xmlns=""><a href="s2431.html">2431-Sample Sequence Listing</a></li>
               <li xmlns=""><a href="s2432-2433.html">2432-2433-[Reserved]</a></li>
               <li xmlns=""><a href="s2434.html">2434-Examination of Patent Applications Claiming Large Numbers of Nucleotide Sequences</a></li>
               <li xmlns=""><a href="s2435.html">2435-Publishing of Patents and Patent Application Publications with Lengthy Sequence Listings</a></li>
            </ul>  </div>
         </div>
      </div>  </div>
      <!-- Footer Navigation: /includes/general/footer2.html -->

<!-- Used in: MPEP, CPC -->

<!-- ID = $Id: footer2.html 3354 2013-04-23 18:43:33Z janaki $ -->

<!-- URL = $URL: https://dev-wmb-svn.etc.uspto.gov/repos/live/active_content/trunk/includes/general/footer2.html $ -->





  <div style="text-align:right"> Last Modified: 

     

    03/27/2014 10:10:34 

  </div>

</div>

</div>




<!-- End of footer2.html -->


   </body>
</html>